Pfizer slashes 2022 earnings outlook despite strong first quarter Covid vaccine and antiviral sales - CNBC

Pfizer said it sold $13.2 billion of its Covid vaccine and $1.5 billion of its antiviral treatment Paxlovid.

Pfizer on Tuesday cut its 2022 earnings guidance, despite reporting first quarter results that beat on the top and bottom line due to strong Covid vaccine and antiviral sales. The pharmaceutical gia… [+3024 chars]

full article...